HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Authors
Keywords
-
Journal
IMMUNOLOGY AND CELL BIOLOGY
Volume 90, Issue 1, Pages 85-94
Publisher
Wiley
Online
2011-11-29
DOI
10.1038/icb.2011.100
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines
- (2017) Marielle Dejligbjerg et al. Cancer Biomarkers
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
- (2011) R. L. Piekarz et al. BLOOD
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma
- (2011) John D. Hainsworth et al. CANCER INVESTIGATION
- Entinostat for treatment of solid tumors and hematologic malignancies
- (2011) Jeffrey Knipstein et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
- (2011) Yanis Boumber et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Histone Deacetylases 9 and 10 Are Required for Homologous Recombination
- (2011) Shweta Kotian et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells
- (2011) Hidemi Rikiishi JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
- (2011) Mark Kirschbaum et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors
- (2011) Giuseppe Giaccone et al. JOURNAL OF CLINICAL ONCOLOGY
- Unfolded protein response in cancer: the Physician's perspective
- (2011) Xuemei Li et al. Journal of Hematology & Oncology
- Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival
- (2011) Stamatios Theocharis et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
- (2011) Yoshihiro Minamiya et al. LUNG CANCER
- Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo
- (2011) G. Dasmahapatra et al. MOLECULAR CANCER THERAPEUTICS
- A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
- (2011) Fabio M. Iwamoto et al. NEURO-ONCOLOGY
- Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells
- (2011) Luca A. Petruccelli et al. PLoS One
- Histone deacetylases as regulators of inflammation and immunity
- (2011) Melanie R. Shakespear et al. TRENDS IN IMMUNOLOGY
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
- (2010) Ruben Niesvizky et al. CANCER
- A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
- (2010) Peter M. Wilson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Two Schedules of Vorinostat in Combination with 5-Fluorouracil and Leucovorin in Patients with Refractory Solid Tumors
- (2010) M. G. Fakih et al. CLINICAL CANCER RESEARCH
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
- (2010) Helen J. Mackay et al. EUROPEAN JOURNAL OF CANCER
- The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
- (2010) Paul A Marks EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance
- (2010) Wenlin Shao et al. INTERNATIONAL JOURNAL OF CANCER
- Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
- (2010) Michael Dickinson et al. INVESTIGATIONAL NEW DRUGS
- Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway
- (2010) Roberto R. Rosato et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lucanthone Is a Novel Inhibitor of Autophagy That Induces Cathepsin D-mediated Apoptosis
- (2010) Jennifer S. Carew et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study
- (2010) Anne M. Traynor et al. Journal of Thoracic Oncology
- Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
- (2010) Suresh S. Ramalingam et al. Journal of Thoracic Oncology
- Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
- (2010) Gregory A. Otterson et al. Journal of Thoracic Oncology
- Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma
- (2010) Sundar Jagannath et al. LEUKEMIA RESEARCH
- MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo
- (2010) R. K. Srivastava et al. MOLECULAR CANCER THERAPEUTICS
- Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining
- (2010) Kyle M Miller et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma
- (2010) Li-Ming Wu et al. PLoS One
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
- (2010) O. Khan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Apoptosis in cancer: Key molecular signaling pathways and therapy targets
- (2009) Claudia Burz et al. ACTA ONCOLOGICA
- A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
- (2009) Monica Galli et al. ANNALS OF HEMATOLOGY
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells
- (2009) C. Urbich et al. BLOOD
- A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
- (2009) A Rocca et al. BRITISH JOURNAL OF CANCER
- Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma
- (2009) Michael Dickinson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis
- (2009) Susan Fotheringham et al. CANCER CELL
- Biomarkers for predicting clinical responses to HDAC inhibitors
- (2009) Lindsay Stimson et al. CANCER LETTERS
- The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer
- (2009) T. Liu et al. CANCER RESEARCH
- Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
- (2009) A. I. Daud et al. CLINICAL CANCER RESEARCH
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells
- (2009) S. Bhalla et al. CLINICAL CANCER RESEARCH
- Targeting of HDAC8 and investigational inhibitors in neuroblastoma
- (2009) Ina Oehme et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A phosphorylation-acetylation switch regulates STAT1 signaling
- (2009) O. H. Kramer et al. GENES & DEVELOPMENT
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
- (2009) E. M. Ocio et al. HAEMATOLOGICA
- A phase 2 study of vorinostat in acute myeloid leukemia
- (2009) E. W. Schaefer et al. HAEMATOLOGICA
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2009) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
- (2009) Axel Hauschild et al. MELANOMA RESEARCH
- HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
- (2009) D. C. Marchion et al. MOLECULAR CANCER THERAPEUTICS
- Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation
- (2009) E Borbone et al. ONCOGENE
- Expression of Hypoxia-Inducible Factor-1α, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic Carcinoma
- (2009) Kotaro Miyake et al. PANCREAS
- Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors
- (2008) Jung-Hyun Park et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
- (2008) R. Rao et al. BLOOD
- Histone deacetylase inhibitors and genomic instability
- (2008) Grégory Eot-Houllier et al. CANCER LETTERS
- HDAC expression and clinical prognosis in human malignancies
- (2008) Wilko Weichert CANCER LETTERS
- HDAC family: What are the cancer relevant targets?
- (2008) Olaf Witt et al. CANCER LETTERS
- Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma
- (2008) V. R. Fantin et al. CANCER RESEARCH
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors
- (2008) N. L. Steele et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
- (2008) L. Ellis et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2008) Susan C. Modesitt et al. GYNECOLOGIC ONCOLOGY
- Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
- (2008) L Marquard et al. HISTOPATHOLOGY
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
- (2008) Robert P. Whitehead et al. INVESTIGATIONAL NEW DRUGS
- Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
- (2008) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
- (2008) A. Miyanaga et al. MOLECULAR CANCER THERAPEUTICS
- Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control
- (2008) Srividya Bhaskara et al. MOLECULAR CELL
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
- (2008) A. J. Frew et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
- (2008) Omar Khan et al. Nature clinical practice. Oncology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now